Alemtuzumab’s Long Term Efficacy for MS Treatment
In this MD Magazine TV video, learn how alemtuzumab, also known as Lemtrada, has proven to be an effective treatment option for multiple sclerosis.
Recently, the results of a study on relapsing-remitting multiple sclerosis (RRMS) patients who had one or more relapses on earlier treatment, showed that alemtuzumab (Lemtrada) improved disability progression over five years, even though most patients received treatment only during the first two years.
The results were recently presented at the Consortium of Multiple Sclerosis Centers (CMSC) 2016 Annual Meeting,
Multiple Sclerosis News Today is strictly a news and information website about the disease. It does not provide medical advice, diagnosis or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.